Funding for this research was provided by:
Received: 12 July 2020
Accepted: 27 August 2020
First Online: 28 September 2020
Ethics approval and consent to participate
: The study was approved by the Institutional Review Board at each respective center.
: All participants were consented to the study and all information has been de-identified prior to publication.
: Dr. Chakravarthy is a consultant to Abbott, Bioness, Medtronic, Nalu Medical, Saluda Medical. He has stock options in Nalu Medical. He is also founder of Newrom Biomedical. Dr. Iwamuro’s workplace, The Department of Research and Therapeutics for Movement Disorders at the Juntendo University Graduate School of Medicine, is an endowment department supported with an unrestricted grant from Medtronic, Boston Scientific, Kyowa Kirin, Boehringer Ingelheim, AbbVie and FP Pharmaceutical. Dr. Ayano Matsui has received honoraria for lectures and writing about SCS from Abbott Medical Japan. There are no other reported conflicts of interest for this body of work from the other authors.